Nebacumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | endotoxin |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Identifiers | |
| CAS Number |
138661-01-5 |
| ATC code | J06BC01 |
| ChemSpider | none |
| KEGG |
D05126 |
| | |
Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]
References
- ↑ Derkx, B.; Wittes, J.; McCloskey, R. (1999). "Randomized, Placebo‐Controlled Trial of HA‐1A, a Human Monoclonal Antibody to Endotoxin, in Children with Meningococcal Septic Shock". Clinical Infectious Diseases 28 (4): 770–726. doi:10.1086/515184. PMID 10825037.
- ↑ WHO: Consolidated List of Products
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.